Jennifer Baldock Sells 10,082 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) insider Jennifer Baldock sold 10,082 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $13.70, for a total transaction of $138,123.40. Following the completion of the sale, the insider owned 332,272 shares of the company’s stock, valued at approximately $4,552,126.40. This represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Surgery Partners Stock Performance

Shares of Surgery Partners stock traded down $0.06 during trading on Monday, hitting $13.30. 1,453,571 shares of the stock were exchanged, compared to its average volume of 1,733,344. The company has a current ratio of 1.87, a quick ratio of 1.71 and a debt-to-equity ratio of 1.15. The company has a fifty day moving average price of $15.16 and a 200-day moving average price of $18.00. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -21.45 and a beta of 1.95. Surgery Partners, Inc. has a 1-year low of $12.25 and a 1-year high of $24.60.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The firm had revenue of $885.00 million during the quarter, compared to analyst estimates of $866.54 million. During the same quarter last year, the business posted $0.44 earnings per share. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. As a group, equities analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners announced that its board has initiated a share buyback plan on Thursday, February 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to repurchase up to 9.7% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Mizuho cut their price target on Surgery Partners from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday. Benchmark restated a “buy” rating on shares of Surgery Partners in a research note on Tuesday, March 3rd. UBS Group reduced their target price on shares of Surgery Partners from $29.00 to $21.00 and set a “buy” rating for the company in a report on Thursday. Royal Bank Of Canada reduced their price objective on Surgery Partners from $31.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, March 4th. Finally, TD Cowen decreased their target price on Surgery Partners from $28.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.45.

Institutional Trading of Surgery Partners

Institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp increased its holdings in shares of Surgery Partners by 313.1% during the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after purchasing an additional 930 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in Surgery Partners by 45,640.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock worth $49,000 after acquiring an additional 2,282 shares during the period. PNC Financial Services Group Inc. raised its holdings in Surgery Partners by 128.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock valued at $58,000 after acquiring an additional 1,519 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Surgery Partners during the 3rd quarter valued at $121,000. Finally, State of Alaska Department of Revenue bought a new position in shares of Surgery Partners in the third quarter worth $151,000.

Key Stories Impacting Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.